Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Jan 31, 2023

SELL
$0.12 - $0.21 $600 - $1,050
-5,000 Reduced 33.33%
10,000 $1,000
Q2 2022

Aug 11, 2022

SELL
$0.41 - $0.91 $2,050 - $4,550
-5,000 Reduced 25.0%
15,000 $6,000
Q1 2022

May 09, 2022

SELL
$0.79 - $1.59 $16,392 - $32,992
-20,750 Reduced 50.92%
20,000 $17,000
Q4 2021

Feb 11, 2022

SELL
$1.36 - $2.94 $6,800 - $14,700
-5,000 Reduced 10.93%
40,750 $55,000
Q3 2021

Oct 27, 2021

SELL
$2.97 - $4.84 $8,910 - $14,520
-3,000 Reduced 6.15%
45,750 $138,000
Q2 2021

Aug 03, 2021

SELL
$3.71 - $5.13 $1.12 Million - $1.54 Million
-301,100 Reduced 86.07%
48,750 $225,000
Q1 2021

Apr 21, 2021

BUY
$4.08 - $14.75 $430,440 - $1.56 Million
105,500 Added 43.18%
349,850 $1.5 Million
Q4 2020

Jan 27, 2021

BUY
$11.06 - $14.01 $2.7 Million - $3.42 Million
244,350 New
244,350 $2.7 Million

Others Institutions Holding ATNX

About Athenex, Inc.


  • Ticker ATNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 156,790,000
  • Market Cap $1.57M
  • Description
  • Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar,...
More about ATNX
Track This Portfolio

Track Ingalls & Snyder LLC Portfolio

Follow Ingalls & Snyder LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ingalls & Snyder LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ingalls & Snyder LLC with notifications on news.